Cargando…
A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial
BACKGROUND: Visceral adiposity in the setting of HIV infection and antiretroviral therapy (ART) is not fully understood, and treatment options remain limited. Telmisartan, an angiotensin receptor blocker and partial PPAR-γ agonist, has been shown to decrease visceral fat and improve metabolic and in...
Autores principales: | Lake, Jordan E., Tseng, Chi-Hong, Currier, Judith S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597631/ https://www.ncbi.nlm.nih.gov/pubmed/23516440 http://dx.doi.org/10.1371/journal.pone.0058135 |
Ejemplares similares
-
Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial
por: Le, Catherine N., et al.
Publicado: (2017) -
Hypertension and microalbuminuria in HIV infected patients: beneficial effects of the treatment with telmisartan
por: Ucciferri, Claudio, et al.
Publicado: (2010) -
Telmisartan and cardioprotection
por: Akhrass, Philippe R, et al.
Publicado: (2011) -
Efficient and improved synthesis of Telmisartan
por: Kumar, A Sanjeev, et al.
Publicado: (2010) -
Telmisartan induced urticarial vasculitis
por: Mahajan, Vikram K., et al.
Publicado: (2015)